It appears that us Abbott stockholders should
stand proud.It seems that the FDA now uses the phrase
"Abbott Syndrome" when talking about other companies like
AHP, when they use tactics that delay manufacturing
changes requested by the FDA. I guess it is better to be
notorious than nothing at all. By the way; how are we doing
with the FDA demands?
haven't we net somewhere before..It might be a
good idea for you to look at NSTK..they are also
working on the apomorhine compound but with nasal
delivery and they have had no side effects at all because
the dosing is much less than Uprima..and the
interaction with saliva, alchol et al seems a lot less..Might
be a good idea for ABT or TAP to talk to NSTK..NSTK
did a small trial against Viagra about 6 months ago
and looked a lot better...Small company but some real
interesting stuff going on, especially in sexual
pain management ...
Quite a turnaround from down 1 1/4 to up
1/2...guess many people really had some doubts about the
drug, and pulling it for a better application will make
the chances better for acceptance and less for
rejection, which is what I think too many people thought
would happen. Since the stock is now heading up...looks
to be the case.
43 was a real ceiling for this
one and now we have a bit of clearer sailing to the
I concur with your analysis. They are making the
prudent decision by delaying the final application to
It appears the investment community feels the same
way. Stock was down only 7/8th.
ABT at these levels is a great buy.
There does appear to be the chance for a silver
lining to the dark cloud. Just when ABT starts to rise
(no pun intended), pulling the plug on Uprima would
seem to be disasterous. BUT.....
1. Full FDA
approval wasn't expected till end of July
press had been lukewarm, esp. with the reported side
3. An addendum submission to an NDA cannot refute or
contradict prior filings. The only way to do that is
withdraw the NDA and then refile.
4. If the delay is
10-12 weeks or less, and it is accompanied with BETTER
NEWS about (ie., reduced incidence of) side effects,
the overall impact could be very positive.
Sounds like TAP/ABT fear a heavy warning from FDA
that could impact UPRIMA & have improved data with
supporting studies to resubmit in 6 months which will give
UPRIMA a big edge on Viagra! This may be smart marketing
rather than get dumped on by FDA!